Browsing by Author "Rowaa Saber"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Beyond erectile dysfunction: Optimization of vardenafil dihydrochloride for hepatic encephalopathy prophylaxis using hybrid lipid polymeric nanoparticles formulation
    (Editions de Sante, 2025-03-06) Marwa H.S. Dawoud; Heba T. Elbalkiny; Yasmeen E.M. Gharib; Sara A.A. Fakkar; Rowaa Saber; Marry E. Yanni; Mai A. Zaafan
    Vardenafil dihydrochloride (VD), a phosphodiesterase-5 (PDE5) is widely used to treat erectile dysfunction, but recent studies suggested its potential for other diseases such as hepatic encephalopathy. However, VD suffers poor solubility and oral bioavailability, and significant first-pass metabolism. This study aims to enhance the bioavailability of VD by employing two combined approaches: formulation of VD into hybrid lipid-polymeric nanoparticles (HLPNPs), and incorporating piperine, a known bioavailability enhancer, to investigate its potential in preventing hepatic encephalopathy. HLPNPs were developed using homogenization/ultrasonication technique, with a one-factor design testing chitosan, oleic acid, or sodium alginate as the helper polymers. Oleic acid showed the best results and was used to prepare the optimized formula (O1), which had a particle size of 128 ± 2.8 nm, a polydispersity index of 0.173 ± 0.07, an entrapment efficiency of 93 ± 1.8 %, and a zeta potential of − 32 ± 1.67 mV. O1 showed a sustained drug release profile, with approximately 70 % of VD released over 72 h. O2 was then prepared with the addition of piperine, resulting in a longer residence time of 717 min compared to O1 (94 min) in the pharmacokinetics study. O1 showed a twofold increase in the bioavailability compared to the unformulated VD while O2 exhibited a ninefold increase. The improvement was confirmed by the higher Cmax from 9 ng/mL for standard VD to 13 ng/mL and 22 ng/mL for O1 and O2, respectively. In hepatic encephalopathy-induced mice model, O2 showed promising efficacy, with significant improvements in liver enzymes, ammonia levels, hippocampal BDNF levels, cGMP levels, and hippocampal GluR1 and P-CREB levels. These findings suggest that combining VD into HLPNPs with piperine is an effective strategy to overcome its bioavailability limitations and enhance its therapeutic potential.